Mcl-1 as a therapeutic target in acute myelogenous leukemia (AML)

Leukemia Research Reports

Volumn 2, Issue 1, 2013, Pages 12-14

  Bose, Prithviraj ^a,b   Grant, Steven ^a,b,c  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

AML; CDK inhibitors; Mcl 1; Obatoclax; Sorafenib

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; CLOFARABINE; CYCLIN DEPENDENT KINASE INHIBITOR; CYTARABINE; DAUNORUBICIN; DINACICLIB; FLAVOPIRIDOL; IDARUBICIN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOXANTRONE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; NAVITOCLAX; OBATOCLAX; PROTEIN BCL 2; PROTEIN MCL 1; ROSCOVITINE; SORAFENIB;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CELL DEATH; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; GENETIC TRANSCRIPTION; HALF LIFE TIME; HUMAN; LOW DRUG DOSE; MITOCHONDRION; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FAMILY; PROTEIN FUNCTION; RNA TRANSLATION;

EID: 84878353201     PISSN: 22130489     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lrr.2012.11.006     Document Type: Article

References (15)

1. Konopleva M., Contractor R., Tsao T., Samudio I., Ruvolo P.P., Kitada S., et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006, 10:375-388.
2. Glaser S.P., Lee E.F., Trounson E., Bouillet P., Wei A., Fairlie W.D., et al. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes and Development 2012, 26:120-125.
3. Chen S., Dai Y., Harada H., Dent P., Grant S. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Research 2007, 67:782-791.
4. Rahmani M., Davis E.M., Bauer C., Dent P., Grant S. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. Journal of Biological Chemistry 2005, 280:35217-35227.
5. Zhang W., Konopleva M., Ruvolo V.R., McQueen T., Evans R.L., Bornmann W.G., et al. Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia 2008, 22:808-818.
6. Konopleva M., Milella M., Ruvolo P., Watts J.C., Ricciardi M.R., Korchin B., et al. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex. Leukemia 2012, 26:778-787.
7. Nguyen M., Marcellus R.C., Roulston A., Watson M., Serfass L., Murthy Madiraju S.R., et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:19512-19517.
8. Konopleva M., Watt J., Contractor R., Tsao T., Harris D., Estrov Z., et al. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Research 2008, 68:3413-3420.
9. Rahmani M., Aust M.M., Attkisson E., Williams D.C., Ferreira-Gonzalez A., Grant S. Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process. Blood 2012, 119:6089-6098.
10. Kasper S., Breitenbuecher F., Heidel F., Hoffarth S., Markova B., Schuler M., et al. Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies. Blood Cancer Journal 2012, 2:e60.
11. Karp J.E., Ross D.D., Yang W., Tidwell M.L., Wei Y., Greer J., et al. Timed Sequential Therapy of Acute Leukemia with Flavopiridol. Clinical Cancer Research 2003, 9:307-315.
12. Karp J.E., Blackford A., Smith B.D., Alino K., Seung A.H., Bolanos-Meade J., et al. Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Leukemia Research 2010, 34:877-882.
13. Ravandi F., Cortes J.E., Jones D., Faderl S., Garcia-Manero G., Konopleva M.Y., et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. Journal of Clinical Oncology 2010, 28:1856-1862.
14. Macdonald D.A., Assouline S.E., Brandwein J., Kamel-Reid S., Eisenhauer E.A., Couban S., et al. Phase I/II study of sorafenib (Bay 43-9006) in combination with low dose cytarabine (LDAC) in elderly patients with AML or high-risk MDS from The NCIC Clinical Trials Group: Trial IND.186. Leukemia and Lymphoma 2012, Nov. 15, [Epub ahead of print].
15. Inaba H., Rubnitz J.E., Coustan-Smith E., Li L., Furmanski B.D., Mascara G.P., et al. Phase I pharmacokinetic and pharmacodynamic study of the mssultikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. Journal of Clinical Oncology 2011, 29:3293-3300.